Updated on 18 September 2013
An interesting finding of the BioSpectrum-CMR study is that China and India, along with South Korea continue to account for more than two-thirds of outsourced clinical trials.
Over the past four years, BioSpectrum Asia in association with CyberMedia Research (CMR) has been capturing the key broad trends in pharmaceutical clinical and contract research organizations (CROs) in the Asia Pacific region through an annual CRO survey.
The BioSpectrum-CMR Asia Pacific CRO Survey, which is in its fifth edition in 2013, has been at the forefront of identifying the latest trends and issues facing the industry and has effectively captured the perspectives and insights of key stakeholders from the CRO industry as well as from sponsors. As many as 90 percent of the CROs surveyed in the region were confident that the market opportunities for full-service and niche CROs (clinical research organizations) will continue to be robust in the next few years. They all expect to bag significant orders from the Big Pharma and develop more strategic partnerships.